Company: MIRM
Filing Date: 2025-11-04
Form Type: 10-Q
Source: 0001759425-25-000054
Chunk: 359

Company: Mirum Pharmaceuticals, Inc.
Filing Date: 2025-11-04
Form: 10-Q
Item: Part I, Item 1
Chunk 359
---
 the three and nine months ended September 30, 2025, respectively, and $5.9 million and $17.1 million for the three and nine months ended September 30, 2024, respectively. Amortization expense was included in cost of sales in the accompanying unaudited condensed consolidated statements of operations. The following table summarizes the estimated future amortization expense associated with the Company’s intangible assets as of September 30, 2025 (in thousands): Amount2025 (remaining three months)5,974 202623,791 202723,575 202823,575 202923,575 Thereafter131,405  $231,895 

14

Accrued ExpensesAccrued expenses consist of the following (in thousands): September 30,2025December 31,2024Accrued sales deductions$55,916 $37,361 Accrued compensation and related benefits36,981 32,248 Accrued royalties payable12,572 9,361 Accrued professional service fees12,889 12,545 Accrued clinical trials11,190 7,148 Accrued contract manufacturing and non-clinical costs8,990 7,555 Accrued interest5,271 2,108 Accrued loss on firm purchase commitments2,348 1,898 Operating lease liabilities, current2,035 1,709 Total accrued expenses and other current liabilities$148,192 $111,933 Other liabilitiesOther liabilities consist of the following (in thousands): September 30,2025December 31,2024Noncurrent accrued sales deductions and other$12,449 $— Noncurrent accrued loss on firm purchase commitments3,532 2,509 Total other liabilities$15,981 $2,509 

6. Asset Acquisitions

License Agreement with Enthorin Therapeutics, LLCIn October 2024, the Company entered into a license agreement with Enthorin Therapeutics, LLC and Dart Neuroscience LLC (“Enthorin”), under which the Company acquired the worldwide rights to develop, manufacture and commercialize a compound designated as ENT-3379, renamed MRM-3379, in exchange for an upfront payment of $7.5 million and up to an additional $217.5 million upon the achievement of regulatory and sales-based milestones as well as mid-single digit percent royalties on